Different arterial cannula size used for FS (15 F) and FF (17 F) approach because of the vessel size is another limitation; however, target ECMO flow of 100 mL/kg/minute was achieved and did not differ in both approaches.
Overall, the rate of achieving MDA did not differ according to PsA clinical subsets (Pearson's χ2 for inter-groups independence P = 0.092).
The FEO2 achieved after preoxygenation did not differ significantly between large and small BVMs (p=0.58, unpaired t test).
At the primary endpoints and all other time points in part 2, the percentages of patients who achieved DAS28 ESR remission did not differ between the IV+SC and subcutaneous golimumab groups (figure 4).
The numbers of patients achieving symptomatic improvement did not differ between study groups for all analysed symptoms (Table 3).
In the present study, efficacy and the time to achieve clinical remission did not differ between the two treatment protocols.
Normalization of the bowel function, which was achieved by 116 (58.9%), did not differ significantly between the laxative regimes or the potency of the regimens (tables 3 and 4).
As the weight loss achieved in both groups did not differ significantly from one another, the present study reinforces the concept that any type of diet can effectively reduce weight and improve metabolic parameters.
The time to first achieving the titration target did not differ significantly between IDeg OD Flex and IGlar OD (estimated hazard ratio 0.91 [0.74–1.11], P = NS) or IDeg OD Flex and IDeg OD (estimated hazard ratio 0.82 [0.67–1.00], P = NS).
